UK markets close in 1 hour 34 minutes

Bio-Rad Laboratories, Inc. (BIO-B)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
279.910.00 (0.00%)
As of 03:59PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 7.98B
Enterprise value 7.78B
Trailing P/E N/A
Forward P/E 25.51
PEG ratio (5-yr expected) 1.06
Price/sales (ttm)3.06
Price/book (mrq)0.91
Enterprise value/revenue 2.91
Enterprise value/EBITDA -11.88

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-25.14%
S&P500 52-week change 325.38%
52-week high 3387.55
52-week low 3271.00
50-day moving average 3318.30
200-day moving average 3333.65

Share statistics

Avg vol (3-month) 3275
Avg vol (10-day) 3N/A
Shares outstanding 55.1M
Implied shares outstanding 628.52M
Float 819.96M
% held by insiders 197.55%
% held by institutions 10.07%
Shares short (15 Apr 2024) 411
Short ratio (15 Apr 2024) 40.58
Short % of float (15 Apr 2024) 40.01%
Short % of shares outstanding (15 Apr 2024) 40.00%
Shares short (prior month 15 Mar 2024) 412

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 308 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -12.37%
Operating margin (ttm)7.32%

Management effectiveness

Return on assets (ttm)1.66%
Return on equity (ttm)-3.43%

Income statement

Revenue (ttm)2.61B
Revenue per share (ttm)90.02
Quarterly revenue growth (yoy)-9.80%
Gross profit (ttm)N/A
EBITDA 495.9M
Net income avi to common (ttm)-322.37M
Diluted EPS (ttm)-21.83
Quarterly earnings growth (yoy)456.70%

Balance sheet

Total cash (mrq)1.65B
Total cash per share (mrq)57.9
Total debt (mrq)1.2B
Total debt/equity (mrq)13.26%
Current ratio (mrq)6.57
Book value per share (mrq)317.38

Cash flow statement

Operating cash flow (ttm)346.57M
Levered free cash flow (ttm)214.28M